Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts
نویسندگان
چکیده
RESEARCH BACKGROUND Currently, multiple myeloma is the second most common hematological malignancy in the U.S., constituting 1% of all cancers. With conventional treatment, the median survival time is typically 3-4 years, although it can be extended to 5-7 years or longer with advanced treatments. Recent research indicated that an increase in osteoclast (OC) activity is often associated withmultiple myeloma (MM) and that a decrease inosteoblast (OB) activity contributesto the osteolytic lesions in MM. Normally, the populations of OCs and OBs are inequilibrium, and an imbalance in this statecontributes to the development of lesions. RESEARCH PROCEDURES A multi-scale agent-based multiple myeloma model was developed to simulate the proliferation, migration and death of OBs and OCs. Subsequently, this model was employed to investigate the efficacy of thethree most commonly used drugs for MM treatment under the following two premises: the reduction in the progression of MM and the re-establishment of the equilibrium between OCs and OBs. RESEARCH PURPOSES The simulated results not only demonstrated the capacity of the model to choose optimal combinations of the drugs but also showed that the optimal use of the three drugs can restore the balance between OCs and OBs as well as kill MMs. Furthermore, the drug synergism analysis function of the model revealed that restoring the balance between OBs and OCs can significantly increase the efficacy of drugs against tumor cells.
منابع مشابه
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
The proteasome inhibitor bortezomib (Velcade) is currently approved as second-line treatment of multiple myeloma (MM). MM-related bone disease is one of the most debilitating complications of MM. Besides supportive care with biphosphonates, which have proven efficacy in reducing and delaying skeletal-related events, there is no specific treatment of lytic bone lesions. The present study investi...
متن کاملInterleukin-27 acts as multifunctional antitumor agent in multiple myeloma.
PURPOSE Multiple myeloma (MM) derives from plasmablast/plasma cells that accumulate in the bone marrow. Different microenvironmental factors may promote metastatic dissemination especially to the skeleton, causing bone destruction. The balance between osteoclast and osteoblast activity represents a critical issue in bone remodeling. Thus, we investigated whether interluekin-27 (IL-27) may funct...
متن کاملMultiple myeloma bone disease: targeting osteoclasts and osteoblasts
Good bone health depends on a balance between bone formation carried out by osteoblasts and bone resorption carried out by osteoclasts. Of the many factors that can tilt this equilibrium, two key molecular signaling pathways stand out. On one side is the receptor activator of nuclear factor B (RANK) / RANK ligand (RANKL) pathway. Here, osteoblasts produce RANKL that binds to its receptor, RANK...
متن کاملIntelligent multi-agent modeling of the interbank network and evaluation of the impact of regulatory policies
agent-based modeling is an emerging computational technique that makes it possible to simulate complex economic systems, including the banking network, with a bottom-up approach. In this paper, the country's banking network is simulated with an intelligent multi-agent modeling model and indicates that these agents behave based on the adaptive learning. This modeling has been done with the aim o...
متن کامل